等待开盘 11-18 09:30:00 美东时间
-0.033
-4.76%
11月17日,Pliant Therapeutics(PLRX)收跌0.55%,报0.69美元,成交额68.11万美元,市值4297.14万美元。 行情数据 ...
11-17 08:28
11月10日,Pliant Therapeutics(PLRX)收跌1.25%,报0.8美元,成交额23.46万美元,市值4951.26万美元。 行情数据 •...
11-10 08:27
Pliant Therapeutics presented preclinical and clinical data on PLN-101095, a dual inhibitor of αvβ8 and αvβ1 integrins, at the SITC Annual Meeting. Blocking these integrins with anti-PD-1 reduced TGF-β signaling, enhancing T cell activation and anti-tumor activity. Biomarker data from the Phase 1 trial showed early immune activation correlates with response to pembrolizumab. PLN-101095 is being evaluated in a Phase 1b trial for ICI-refractory sol...
11-09 13:30
11月3日,Pliant Therapeutics(PLRX)收跌2.29%,报0.84美元,成交额32.66万美元,市值5196.46万美元。 行情数据 •...
11-03 08:21
Pliant Therapeutics announced two poster presentations at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) about PLN-101095, a dual-selective integrin inhibitor. The first presentation, by Nika Rajabian, focuses on targeting αvβ8 and αvβ1 integrins to enhance anti-tumor responses with immune checkpoint inhibition. The second, by Martin Decaris, explores plasma biomarkers predicting sensitivity to PLN-101095 in advanced so...
10-29 20:05
10月27日,Pliant Therapeutics(PLRX)收跌1.6%,报0.85美元,成交额25.37万美元,市值5262.08万美元。 行情数据 •...
10-27 07:23
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:25
Pliant Therapeutics appoints David Raben, M.D., as Chief Medical Officer. With over 30 years of oncology expertise, Raben brings significant experience in drug development and clinical trials. His leadership is expected to advance the company's PLN-101095 program, a targeted therapy for solid tumors. Raben previously led clinical development at Bicara Therapeutics and held key roles at Amgen and Genentech, focusing on innovative cancer treatments...
09-30 20:10
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatme...
08-18 20:35
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share from the same period last year.
08-12 04:21